The companies also agreed to establish a working group to explore the development of standard formulas and definitions for the validation of genomic profiling assays.
The firm's Guardant360 assay will be used first to test patients for ERBB2 mutations, then guide patients to a variety of treatment arms.
Companies in the life science tools and molecular diagnostics spaces provided updates on their businesses at the 36th annual JP Morgan Healthcare Conference this week in San Francisco.
Technologies gained one of their first solid footholds in the clinical care of cancer patients with adoption into the treatment paradigm of lung cancer, while researchers turned their eyes to proving utility in other niches.
There were fewer mergers and acquisitions in the omics space in 2017, breaking a two-year streak of growth — however, the deals themselves stayed fairly large.
The partners will use the GuardantOMNI assay, a 500-plus-gene liquid biopsy panel designed to accelerate clinical trials and targeted cancer therapy research.
The researchers found that most advanced EGFR-mutant lung cancer patients harbored changes in an average of two to three other oncogenes.
The results of the study could have implications for liquid biopsy developers that aim to pick out patients more likely to respond to immunotherapies.
Guardant is providing its Guardant 360 CDx test for a clinical trial of Merck's small molecule, c-Met kinase inhibitor called tepotinib.
In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.
An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.
In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.
In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.